Claims
- 1. A method for treating a mammal afflicted with a disease in which an IL-20 polypeptide plays a role, wherein the IL-20 polypeptide is comprised of an amino acid sequence selected from the group consisting of SEQ ID Nos.: 1, 2, 3, 4, 5, 6, 7, 8 and 9, comprising:
administering antagonist of said IL-20 polypeptide to said individual.
- 2. The method of claim 1 wherein the antagonist is selected from the group consisting of an antibody, antibody fragment or single chain antibody that binds to said IL-20 polypeptide, a soluble receptor that binds to said IL-20 polypeptide and an antibody, antibody fragment or single chain antibody which binds to the soluble receptor of IL-20 wherein said soluble receptor is comprised of an IL-20RA subunit and an IL-20RB subunit.
- 3. The method of claim 2 wherein the soluble receptor is a comprised of the extracellular domain of IL-20RA and the extracellular domain of IL-20RB.
- 4. The method of claim 3 wherein the extracellular domain of IL-20RA is fused to a constant region heavy chain of an immunoglobulin (Ig) molecule, and the extracellular domain of IL-20RB is fused to a constant region of a light chain of an Ig molecule.
- 5. The method of claim 2 wherein the antibody, antibody fragment or single chain antibody, which binds to the IL-20 receptor, binds to the IL-20RA subunit.
- 6. The method of claim 2 wherein the antibody, antibody fragment or single chain antibody, which binds to the IL-20 receptor, binds to the IL-20RB subunit.
- 7. The method of claim 1 wherein the disease that the IL-20 polypeptide plays a role is a skin disease selected from the group consisting of psoriasis, eczema, atopic dermatitis and contact dermatitis.
- 8. The method of claim 1 wherein the disease that the IL-20 polypeptide plays a role is an inflammatory lung selected from the group consisting of adult respiratory disease, asthma, bronchitis and pneumonia.
- 9. A method for promoting the expression of IL-8 in a cell comprising bringing the cell into contact with IL-20.
- 10. A method for increasing the expression of IL-8 in an individual comprising administering IL-20 to said individual.
Parent Case Info
[0001] This claims the benefit of U.S. Provisional application No. 60/171,969, filed Dec. 23, 1999 and U.S. Provisional application No. 60/213,341 filed Jun. 22, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60171969 |
Dec 1999 |
US |
|
60213341 |
Jun 2000 |
US |